Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: Lower rates for 5 years post chemotherapy.

Genetics in medicine : official journal of the American College of Medical Genetics - 1 Sept 2024

Evans D Gareth, Morgan Robert D, Crosbie Emma J, Howell Sacha J, Forde Claire, Howell Anthony, Lalloo Fiona, Woodward Emma R

Abstract excerpt

PURPOSE: The identification of germline BRCA1/BRCA2 pathogenic variants (PV) infer high remaining lifetime breast/ovarian cancer risks, but there is paucity of studies assessing breast cancer risk after ovarian cancer diagnosis. METHODS: We reviewed the history of breast cancer in 895 PV heterozygotes (BRCA1 = 541). Cumulative annual breast cancer incidence was assessed at 2, 5, 10, and >10 years after ovarian...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Breast Neoplasms

Share to Germ-Line Mutation

Share to Heterozygote

Share to Incidence

Share to Ovarian Neoplasms

Source

Identifiers

PMID: 38847192
DOI: 10.1016/j.gim.2024.101172

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: Lower rates for 5 years post chemotherapy.PMID 38847192Read ↗

Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant.Semantic proximity Read ↗

Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2.Semantic proximity Read ↗

Breast cancer following ovarian cancer in BRCA mutation carriers.Semantic proximity Read ↗

Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.Semantic proximity Read ↗

Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.Semantic proximity Read ↗

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.Semantic proximity Read ↗

Germline Mutation in <i>BRCA1</i> or <i>BRCA2</i> and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian CancerSemantic proximity Read ↗

Effect of breast cancer after ovarian cancer on mortality for BRCA mutation carriers.Semantic proximity Read ↗

Postpartum Breast Cancer and Survival in Women With Germline BRCA Pathogenic Variants.Semantic proximity Read ↗

Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status.Semantic proximity Read ↗

Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.